source
- Ensoma cuts staff again to focus on lead gene therapy for rare immune diseaseBoston‑based biotech Ensoma announced another round of layoffs as it narrows its efforts to its sole clinical candidate, EN‑374, aimed at treating X‑linked chronic granulomatous disease (X‑CGD). E…
- BlossomHill and Latigo close IPO week with $496 million raisedBlossomHill Therapeutics, a cancer‑focused biotech, completed its initial public offering this week. Latigo, a company developing non‑opioid pain treatments, also went public at the same time. To…